Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00094328
Other study ID # D6873C00047
Secondary ID BATT
Status Completed
Phase Phase 2
First received
Last updated
Start date November 22, 2004
Est. completion date December 6, 2017

Study information

Verified date June 2018
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to investigate whether bicalutamide given in combination with anastrozole once daily for 12 months is effective in treating testotoxicosis in boys. Testotoxicosis is a condition that causes early puberty in boys including growth in height, and development of muscles and sexual organs .


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date December 6, 2017
Est. primary completion date May 22, 2008
Accepts healthy volunteers No
Gender Male
Age group 2 Years to 13 Years
Eligibility Inclusion Criteria:

- Provision of written informed consent of parent/legal guardian and subject assent (as needed by local requirements)

- Male aged 2 years and over

- Diagnosis of testotoxicosis based on the following:

- Clinical features of Progressive sexual precocity documented by Tanner staging and evidence of symmetrical testicular enlargement

- Clinical features of significantly advanced bone age (defined as bone age of at least 12 months beyond chronological age)

- Pubertal levels of serum testosterone

- Prepubertal levels of serum gonadotropins

- Lack of an increase in serum gonadotropin levels following GnRH stimulation

- Other pathology excluded by:

- Undetectable plasma b human chorionic gonadotropin (bHCG). Samples with values below the LOQ will be reported as "<10 IU/L" which in the clinical setting equate to 'undetectable'.

- Normal levels of 17-hydroxyprogesterone (17-OHP)

- Normal levels of dehydroepiandrosterone sulphate (DHEAS)

- Naive to anti androgen receptor therapy:

(Note: Ketoconazole and Spironolactone are considered acceptable as is prior use of anastrozole or other aromatase inhibitors)

- A documented reliable height measurement taken > 6 months prior to study enrollment. Additionally for subjects who have previously received ketoconazole or spironolactone treatment, a documented reliable height measurement taken immediately prior to beginning this treatment.

(Note: for subjects who received such previous treatment only a single assessment is needed if it was taken immediately prior to beginning treatment and > 6 months prior to study entry)

- Subjects should be free of endocrine or other effects of previous treatment for testotoxicosis prior to study entry: to ensure this there should be 15 days or 4 drug half lives (whichever is the longer) washout period from prior medication for testotoxicosis.

Exclusion Criteria:

- Evidence of central precocious puberty as demonstrated by GnRH stimulation test

- Serum concentration of total or direct bilirubin, GGT, AST or ALT greater than 1.5 times the upper limit of normal for age

- Serum concentration of creatinine greater than 1.5 times the upper limit of normal for age

- Any concomitant medical condition that, in the opinion of the investigator, may expose a subject to an unacceptable level of safety risk or that affects subject compliance

- Known hypersensitivity to any of the study medications

- Participation in a clinical study at the time of enrollment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bicalutamide
oral
Anastrozole
oral

Locations

Country Name City State
Canada Research Site London Ontario
France Research Site Montpellier Cedex
India Research Site Chennai
India Research Site New Dehli
Russian Federation Research Site Moscow
United Kingdom Research Site London
United States Research Site Birmingham Alabama
United States Research Site Greenville South Carolina
United States Research Site Indianapolis Indiana
United States Research Site Jacksonville Florida
United States Research Site Minneapolis Minnesota
United States Research Site Philadelphia Pennsylvania
United States Research Site Spokane Washington
United States Research Site Temple Texas
United States Research Site Tulsa Oklahoma

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Countries where clinical trial is conducted

United States,  Canada,  France,  India,  Russian Federation,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Growth Rate (cm/Year) Change in growth rate after 12 months relative to the growth rate during the =6 month pre-study period, based on raw height data (cm/year). Assessed after 12 months treatment
Primary Change in Growth Rate (SD Units) Change in growth rate after 12 months relative to the growth rate during the =6 month pre-study period, calculated after adjustment for the chronological age of the patient (expressed as a standard deviation [SD] score). Assessed after 12 months treatment
Secondary Change in Growth Rate (cm/Year) Change in growth rate after 6 months of treatment relative to the growth rate during the =6 months pre-study period. Assessed after 6 months treatment
Secondary Change in Growth Rate (SD Units) Change in growth rate after 6 months of treatment relative to the growth rate during the =6 months pre-study period. Assessed after 6 months treatment
Secondary Change in Bone Age Maturation Rate (cm/Year) Radiographs were used to assess the bone age at =6 months pre-study, baseline, 6 and 12 months. The rate of change in bone age at baseline was calculated from a radiograph taken at least 6 months prior to study enrolment. The change in bone maturation after 6 months of treatment was calculated relative to the rate of change in bone age during the = 6 months pre-study period. Assessed after 6 and 12 months treatment
Secondary Change in Bone Age to Chronological Age Ratio Change in bone age to chronological age ratio after 6 and 12 months treatment relative to the baseline ratio for all patients. Assessed after 6 and 12 months of treatment
Secondary Number of Patients With Height Between 5th and 95th Percentile The number of patients whose height lies between the 5th and 95th percentiles (using the percentile tables on the WHO database) for chronological age at the 12 month assessment. Assessed after 3, 6, 9 and 12 months of treatment
Secondary Change in Predicted Adult Height (PAH) Radiographs are used to assess the bone age, the change in predicted adult height (PAH) is calculated from the bone age using the Bayley and Pinneau Method. The change in PAH is be calculated by subtracting the PAH at baseline from the PAH at 12 months. Assessed after 12 months treatment
Secondary Change in Average Testicular Volume Testicular volume of both testes was measured using either ultrasound or an orchidometer. Testicular volume was measured at baseline and at 6 and 12 months. The change in testicular volume from baseline was calculated for the left and right testicle as well as the average across both testes by subtracting the baseline volume from the volumes at 6 and 12 months within each patient. Assessed after 6 and 12 months of treatment
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05957991 - Danish Precocious Puberty Study - DAPP Study A National Cohort Study on Incidence and Etiologies for Precocious Puberty
Completed NCT04012632 - Kisspeptin/GPR54 Pathway and Early Puberty
Completed NCT02431416 - Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Premature Puberty N/A
Recruiting NCT06083415 - Early Breast Growth in Girls Aged 6 to 8 Years in the Current Environmental Context N/A
Not yet recruiting NCT06263868 - First Observatory of Precocious Puberty.
Completed NCT00635817 - A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty Phase 3
Completed NCT00278915 - Faslodex in McCune-Albright Syndrome Phase 2
Completed NCT00494169 - Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders
Completed NCT00660010 - Study of Lupron Depot In The Treatment of Central Precocious Puberty Phase 3
Recruiting NCT04884620 - The 3rd COPENHAGEN Puberty Study
Active, not recruiting NCT03628937 - The Effect of Decaffeinated Green Tea Polyphenol Intake on the Risk of Precocious Puberty Among Obese Girls N/A
Enrolling by invitation NCT02790112 - Long-term Outcome of GnRH Analogues Treatment of Children With Idiopathic Central Precocious Puberty N/A